Pay in 4 interest-free payments of $5.57 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Klusener, G.J
Summary Hims expects $2.3-2.4 billion in revenue for 2025, with $725 million from weight loss The decision to continue compounding semaglutide (GLP-1s) is controversial given the FDA has declared the shortage over Hims is likely operating within the law and should be able to defend itself against potential FDA actions and third-party litigation On February 24, 2025, Hims & Hers Health, Inc
The drug was the only thing which was different between these two groups, he said
The GLP-1 Receptor Agonist Market is evolving rapidly through these strategic moves
US$ 29.19
US$ 27.37
US$ 23.70
US$ 27.88
US$ 25.33
US$ 21.98
US$ 29.10
US$ 25.39
US$ 21.43
US$ 28.77
US$ 25.99
